Ono Pharmaceutical Co., Ltd.

Other

Tasuku Honjo

Kyoto University

Japan Tobacco Inc.

Suntory Limited

Takeda Chemical Industries, Inc.

Japan Science and Technology Corporation

Ono Pharmaceuticals Co., Ltd.

Ono Pharmaceuticalco.,ltd.

Sysmex Corporation

Honjo, Tasuku

Shiro Shibayama

Kei Tashiro

Nagahiro Minato

Yoshiko Iwai

Takao Yoshida

Masayoshi Matsuo

Masakazu Miyamoto

Kazuhiko Takeda

Kazuhiro Kobuke

Hideaki Tada

Jun Takahashi

Fumihiko Matsuda

Hiroki Toda

Masamichi Muramatsu

Eva Severinson

Takashi Shinohara

Kiyoshi Takatsu

Michio Shirozu

Yasumasa Ishida

Akira Shimizu

Masaya Ikegawa

Yasushi Okuno

Hiroyuki Nishimura

Taku Okazaki

Kazuko Matsumoto

Tomoyuki Nakamura

Sidonia Fagarasan

Hitoshi Uga

Kenji Chamoto

Shiro c/o Ono Pharmaceutical Co Ltd Shibayama

Yoshiko c/o The Rockefeller University Iwai

Megumi Goto

The present invention provides markers for judging the efficacy of therapy with a PD-1 signal inhibitor before or at an early stage of the therapy. As biomarkers for predicting or judging the efficacy of therapy with a PD-1 signal inhibitor, surrogate indicators of metabolic changes relating to mitochondrial activity in T cells and/or T cell activation in a subject are used. As such indicators, intestinal flora-related metabolites in the serum or plasma, energy metabolism-related metabolites in the serum or plasma, amino acid metabolism-related metabolites and/or derivatives thereof in the serum of plasma, oxygen consumption rate and/or ATP turnover in peripheral blood CD8cells, amino acids in T cells, and T-bet in peripheral blood CD8cells may be used.

Efficacy determination markers in disease treatment by PD-1 signal inhibitor

The present invention relates to a substance specific to human PD-1 comprising a part that recognizes human PD-1, a part that recognizes a membrane protein in cell membrane of human PD-1-expressing cells, and linkers. Since the substance specific to human PD-1 selectively can recognize human PD-1 and a membrane protein on cell membrane of human PD-1-expressing cells and can transmit inhibitory signal of human PD-1, it is useful for therapy and/or prevention of diseases caused by immunopathy.

Substance specific to human PD-1

Compositions for cancer or infection treatment via immunopotentiation caused by inhibition of immunosuppressive signal induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient, screening methods of the substrates for cancer or infection treatment, cell lines used for the screening methods, evaluation methods that selects the substrates for cancer treatment, and carcinoma cell transplanted mammals used for the evaluation methods. The compositions of the present invention that inhibits the function of PD-1, PD-L1, PD-L2 are useful for cancer or infection treatment.

Immunopotentiative composition

Compositions for cancer or infection treatment via immunopotentiation caused by inhibition of immunosuppressive signal induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient, screening methods of the substrates for cancer or infection treatment, cell lines used for the screening methods, evaluation methods that select the substrates for cancer treatment, and carcinoma cell transplanted mammals used for the evaluation methods. The compositions of the present invention that inhibits the function of PD-1, PD-L1, or PD-L2 are useful for treatment of cancer or infection.

Compositions for cancer or infection treatment via immunopotentiation caused by inhibition of immunosuppressive signal induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient, screening methods of the substrates for cancer or infection treatment, cell lines used for the screening methods, evaluation methods that selects the substrates for cancer treatment, and carcinoma cell transplanted mammals used for the evaluation methods. The compositions of the present invention that inhibits the function of PD-1, PD-L1 PD-L2 are useful for cancer or infection treatment.

Compositions for cancer or infection treatment via immunopotentiation caused by inhibition of immunosuppressive signal induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient, screening methods of the substrates for cancer or infection treatment, cell lines used for the screening methods, evaluation methods that selects the substrates for cancer treatment, and carcinoma cell transplanted mammals used for the evaluation methods. The compositions of the present invention that inhibits the function of PD-1, PD-L1, or PD-L2 are useful for cancer or infection treatment.

Treatment method using anti-PD-L1 antibody

The invention discloses a useful and novel factor (polypeptide) which plays an important role for morbid vascular smooth muscle in restenosis after percutaneous transluminal coronary angioplasty (PTCA) and arterial sclerosis in the field of cardiovascular system.

Polypeptide ESDN, polynucleotides encoding the polypeptide, and utility of the polypeptide

Compounds that can recognize selectively both PD-1 protein and a membrane protein co-existing with PD-1 on a cell membrane, and can transmit a suppressive signal of PD-1. The compounds are useful for medical treatment and/or prevention of diseases caused by immune abnormality.

Substance that specifically recognizes PD-1

The invention discloses a useful and novel factor (polypeptide) which plays an important role for morbid vascular smooth muscle in restenosis after percutaneous transluminal coronany angioplasty (PTCA) and arterial sclerosis in the field of cardiovascular system.

Growing community of inventors

Kyoto, Japan

Tasuku Honjo